Clinical Trial

Electrochemotherapy-Induced Changes in Tumor Microenvironment in Cutaneous Melanoma

Recruiting
View on ClinicalTrials.gov →
Summary
Cutaneous melanoma frequently develops cutaneous and subcutaneous metastases, which may cause significant morbidity and negatively affect quality of life. Electrochemotherapy (ECT) is an established local treatment modality for cutaneous and subcutaneous tumor lesions that combines the administration of cytotoxic drugs with the application of electric pulses to increase drug uptake into tumor cells. In addition to its direct cytotoxic effects, electrochemotherapy may induce changes in the tumor microenvironment, including immune cell infiltration, vascular alterations, and other biological responses that could influence tumor control. The aim of this study is to evaluate changes in the tumor microenvironment of cutaneous and subcutaneous melanoma metastases following electrochemotherapy with either intravenous bleomycin or intratumoral cisplatin. Tumor tissue samples collected before and after treatment will be analyzed to characterize microenvironmental changes and to compare treated and untreated lesions. The results of this study may improve understanding of biological effects of electrochemotherapy in melanoma metastases and support further development of treatment strategies.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-02-04.
Trial Details
NCT Number NCT07404605
Lead Sponsor Institute of Oncology Ljubljana
Conditions MELANOMA, SKIN NEOPLASMS
Enrollment 150 participants
Start Date 2023-09-01
Primary Completion 2025-09-30 (estimated)
Study Completion 2026-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-02-19